Data Insights

Upadacitinib ER by AbbVie for Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease): Likelihood of Approval

Upadacitinib ER is under clinical development by AbbVie and currently in Pre-Registration for Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease)....

Likelihood of Approval and Phase Transition Success Rate Model - Upadacitinib ER in Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease)

Data Insights

Venetoclax by AbbVie for Secondary Acute Myeloid Leukemia: Likelihood of Approval

Venetoclax is under clinical development by AbbVie and currently in Phase II for Secondary Acute Myeloid Leukemia. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Venetoclax in Secondary Acute Myeloid Leukemia

Data Insights

Venetoclax by AbbVie for Aplastic Anemia: Likelihood of Approval

Venetoclax is under clinical development by AbbVie and currently in Phase II for Aplastic Anemia. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Venetoclax in Aplastic Anemia

Data Insights

Venetoclax by AbbVie for Mantle Cell Lymphoma: Likelihood of Approval

Venetoclax is under clinical development by AbbVie and currently in Phase III for Mantle Cell Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Venetoclax in Mantle Cell Lymphoma

Data Insights

Ibrutinib by AbbVie for Splenic Marginal Zone B-Cell Lymphoma: Likelihood of Approval

Ibrutinib is under clinical development by AbbVie and currently in Phase III for Splenic Marginal Zone B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Ibrutinib in Splenic Marginal Zone B-Cell Lymphoma

Data Insights

Ibrutinib by AbbVie for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval

Ibrutinib is under clinical development by AbbVie and currently in Phase III for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid...

Likelihood of Approval and Phase Transition Success Rate Model - Ibrutinib in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma)

Data Insights

Ibrutinib by AbbVie for Nodal Marginal Zone B-Cell Lymphoma: Likelihood of Approval

Ibrutinib is under clinical development by AbbVie and currently in Phase III for Nodal Marginal Zone B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Ibrutinib in Nodal Marginal Zone B-Cell Lymphoma

Data Insights

Navitoclax dihydrochloride by AbbVie for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis): Likelihood of Approval

Navitoclax dihydrochloride is under clinical development by AbbVie and currently in Phase III for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis). According...

Likelihood of Approval and Phase Transition Success Rate Model - Navitoclax Dihydrochloride in Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis)

Data Insights

Lutikizumab by AbbVie for Hidradenitis Suppurativa: Likelihood of Approval

Lutikizumab is under clinical development by AbbVie and currently in Phase III for Hidradenitis Suppurativa. According to GlobalData, Phase III...

Likelihood of Approval and Phase Transition Success Rate Model - Lutikizumab in Hidradenitis Suppurativa

Data Insights

Venetoclax by AbbVie for Transformed Mycosis Fungoides: Likelihood of Approval

Venetoclax is under clinical development by AbbVie and currently in Phase II for Transformed Mycosis Fungoides. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Venetoclax in Transformed Mycosis Fungoides

Data Insights

Venetoclax by AbbVie for Natural Killer Cell Lymphomas: Likelihood of Approval

Venetoclax is under clinical development by AbbVie and currently in Phase I for Natural Killer Cell Lymphomas. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Venetoclax in Natural Killer Cell Lymphomas

Data Insights

Venetoclax by AbbVie for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval

Venetoclax is under clinical development by AbbVie and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Venetoclax in Peripheral T-Cell Lymphomas (PTCL)

Data Insights

Venetoclax by AbbVie for Myeloproliferative Disorders: Likelihood of Approval

Venetoclax is under clinical development by AbbVie and currently in Phase II for Myeloproliferative Disorders. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Venetoclax in Myeloproliferative Disorders

Data Insights

Venetoclax by AbbVie for Solid Tumor: Likelihood of Approval

Venetoclax is under clinical development by AbbVie and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Venetoclax in Solid Tumor

Data Insights

Venetoclax by AbbVie for Amyloidosis: Likelihood of Approval

Venetoclax is under clinical development by AbbVie and currently in Phase II for Amyloidosis. According to GlobalData, Phase II drugs...

Likelihood of Approval and Phase Transition Success Rate Model - Venetoclax in Amyloidosis

Data Insights

Elsubrutinib by AbbVie for Systemic Lupus Erythematosus: Likelihood of Approval

Elsubrutinib is under clinical development by AbbVie and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Elsubrutinib in Systemic Lupus Erythematosus

Data Insights

Telisotuzumab vedotin by AbbVie for Non-Small Cell Lung Cancer: Likelihood of Approval

Telisotuzumab vedotin is under clinical development by AbbVie and currently in Phase III for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Telisotuzumab Vedotin in Non-Small Cell Lung Cancer

Data Insights

Budigalimab by AbbVie for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval

Budigalimab is under clinical development by AbbVie and currently in Phase II for Metastatic Adenocarcinoma of The Pancreas. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Budigalimab in Metastatic Adenocarcinoma of The Pancreas

Data Insights

Serclutamab talirine by AbbVie for Glioblastoma Multiforme (GBM): Likelihood of Approval

Serclutamab talirine is under clinical development by AbbVie and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Serclutamab Talirine in Glioblastoma Multiforme (GBM)

Data Insights

Risk adjusted net present value: What is the current valuation of AbbVie's Telisotuzumab Vedotin?

Telisotuzumab Vedotin is a monoclonal antibody conjugated commercialized by AbbVie, with a leading Phase III program in Non-Small Cell Lung...

Net Present Value Model: AbbVie Inc's Telisotuzumab Vedotin